These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14618632)

  • 1. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.
    Tuve S; Wagner SN; Schittek B; Pützer BM
    Int J Cancer; 2004 Jan; 108(1):162-6. PubMed ID: 14618632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative TP73 transcript analysis in hepatocellular carcinomas.
    Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM
    Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines.
    Schittek B; Sauer B; Garbe C
    Int J Cancer; 1999 Aug; 82(4):583-6. PubMed ID: 10404074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.
    Stiewe T; Theseling CC; Pützer BM
    J Biol Chem; 2002 Apr; 277(16):14177-85. PubMed ID: 11844800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p.
    Kilic E; Brüggenwirth HT; Meier M; Naus NC; Beverloo HB; Meijerink JP; Luyten GP; de Klein A
    Melanoma Res; 2008 Jun; 18(3):208-13. PubMed ID: 18477895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia.
    Meier M; den Boer ML; Meijerink JP; Broekhuis MJ; Passier MM; van Wering ER; Janka-Schaub GE; Pieters R
    Leukemia; 2006 Aug; 20(8):1377-84. PubMed ID: 16791269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas.
    Kroiss MM; Bosserhoff AK; Vogt T; Buettner R; Bogenrieder T; Landthaler M; Stolz W
    Melanoma Res; 1998 Dec; 8(6):504-9. PubMed ID: 9918412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transactivation-deficient DeltaTA-p73 acts as an oncogene.
    Stiewe T; Zimmermann S; Frilling A; Esche H; Pützer BM
    Cancer Res; 2002 Jul; 62(13):3598-602. PubMed ID: 12097259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas.
    Tuve S; Racek T; Niemetz A; Schultz J; Soengas MS; Pützer BM
    Apoptosis; 2006 Feb; 11(2):235-43. PubMed ID: 16502261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
    Emmrich S; Wang W; John K; Li W; Pützer BM
    Mol Cancer; 2009 Aug; 8():61. PubMed ID: 19671150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
    Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
    Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
    Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
    J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.
    Sayan AE; Sayan BS; Findikli N; Ozturk M
    Oncogene; 2001 Aug; 20(37):5111-7. PubMed ID: 11526499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
    Zaika AI; Kovalev S; Marchenko ND; Moll UM
    Cancer Res; 1999 Jul; 59(13):3257-63. PubMed ID: 10397274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
    Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational and expression analysis of the p73 gene in melanoma cell lines.
    Tsao H; Zhang X; Majewski P; Haluska FG
    Cancer Res; 1999 Jan; 59(1):172-4. PubMed ID: 9892203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of p63 and p73 expression.
    Waltermann A; Kartasheva NN; Dobbelstein M
    Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
    Muttray AF; Cox RL; Reinisch CL; Baldwin SA
    Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
    Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
    J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.